Stock 600976 JIANMIN PHARMACEUTICAL GROUP CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Jianmin Pharmaceutical Group Co.,Ltd.

Equities

600976

CNE000001HB7

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
56.35 CNY +1.28% Intraday chart for Jianmin Pharmaceutical Group Co.,Ltd. -0.74% -13.64%
Apr. 19 Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 16 Jianmin Pharma Gets Nod to Market Asthma Drug MT

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • The company returns high margins, thereby supporting business profitability.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

  • The company appears highly valued given the size of its balance sheet.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
JIANMIN PHARMACEUTICAL GROUP CO.,LTD. Stock Jianmin Pharmaceutical Group Co.,Ltd.
-13.64% 1.17B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.24% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.37% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.16% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.97% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
B+
NOVARTIS AG Stock Novartis AG
+4.71% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
A+
AMGEN INC. Stock Amgen Inc.
-4.10% 145B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 600976 Stock
  4. Ratings Jianmin Pharmaceutical Group Co.,Ltd.